4）病態からみえてきた炎症性腸疾患治療―現在そして未来にむけて
Saved in:
| Published in | 日本内科学会雑誌 Vol. 109; no. 9; pp. 1759 - 1763 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本内科学会
10.09.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-5384 1883-2083 |
| DOI | 10.2169/naika.109.1759 |
Cover
| Author | 仲瀬, 裕志 |
|---|---|
| Author_xml | – sequence: 1 fullname: 仲瀬, 裕志 organization: 札幌医科大学消化器内科学講座 |
| BookMark | eNo9kM1Kw0AUhQepYK3d-hapM5lMOllq8Q8KbnTlItxOJ5paqyTduOsEipai4kKD0OJC_EF3rgSlvouDiTtfwVjFzT1wz-HA-aZRrrXXkgjNElwyie3MtcDfgRLBTomUmTOB8oRzapiY0xzKY2wSg1FuTaFiGPo1bFGbcUKtPNq0vl57adxNun2t-jrqafWm1ZFWt1oda3WVRidpfJh07j67z-nFKImuk6eX9DJ675ynp6OPwb1WQ63iLJ8MHpLhjVaPOupodZZ9ZtCkB81QFv-0gDaWFtcrK0Z1bXm1Ml81GoRxbFDCPYeXwfSEyakEJqEuLA-4U-ceEIEzDwSz66LGJMeMM8uzCcky0pEi21JAC7-9jbANW9LdD_xdCA5cCNq-aEp3zMbN2LjO-P4Q-jfFNgRuA-g3yPOAyA |
| ContentType | Journal Article |
| Copyright | 2020 一般社団法人 日本内科学会 |
| Copyright_xml | – notice: 2020 一般社団法人 日本内科学会 |
| DOI | 10.2169/naika.109.1759 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1883-2083 |
| EndPage | 1763 |
| ExternalDocumentID | article_naika_109_9_109_1759_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS DIK F5P JSF OK1 RJT |
| ID | FETCH-LOGICAL-j1580-318f987a2fc283ea5eadc4fa89d8fa1c087aac56dcb5e805854f611dc4e9ec043 |
| ISSN | 0021-5384 |
| IngestDate | Wed Sep 03 06:31:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 9 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j1580-318f987a2fc283ea5eadc4fa89d8fa1c087aac56dcb5e805854f611dc4e9ec043 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/naika/109/9/109_1759/_article/-char/ja |
| PageCount | 5 |
| ParticipantIDs | jstage_primary_article_naika_109_9_109_1759_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2020/09/10 |
| PublicationDateYYYYMMDD | 2020-09-10 |
| PublicationDate_xml | – month: 09 year: 2020 text: 2020/09/10 day: 10 |
| PublicationDecade | 2020 |
| PublicationTitle | 日本内科学会雑誌 |
| PublicationTitleAlternate | 日内会誌 |
| PublicationYear | 2020 |
| Publisher | 一般社団法人 日本内科学会 |
| Publisher_xml | – name: 一般社団法人 日本内科学会 |
| References | 9) Nakase H, et al: Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther 46: 873-882, 2017. 7) Forkel M, et al: Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn's disease and ulcerative colitis. J Crohns Colitis 13: 67-78, 2019. 2) Cooney R, et al: NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16: 90-97, 2010. 11) Yoshino T, et al: Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis 16: 2022-33, 2010. 4) Smith PD, et al: Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 206: 149-159, 2005. 13) Sandborn WJ, et al: Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376: 1723-1736, 2017. 17) Vermeire S, et al: The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 60: 1068-1075, 2011. 1) Fritz T, et al: Crohn's disease: NOD2, autophagy and ER stress converge. Gut 60: 1580-1588, 2011. 5) Denning TL, et al: Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 8: 1086-1094, 2007. 15) Christensen B, et al: Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol 17: 486-493, 2019. 12) Vijayakrishnan L, et al: Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 32: 25-34, 2011. 3) Smythies LE, et al: Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115: 66-75, 2005. 10) Arseneau KO, Cominelli F: Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther 97: 22-28, 2015. 16) Danese S, Panés J: Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 147: 981-989, 2014. 14) Scribano ML: Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence. World J Gastroenterol 24: 2457-2467, 2018. 8) Yamada S, et al: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol 14: 80, 2014. 18) Sandborn WJ, et al: Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374: 1754-1762, 2016. 6) Kamada N, et al: Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 118: 2269-2280, 2008. |
| References_xml | – reference: 7) Forkel M, et al: Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn's disease and ulcerative colitis. J Crohns Colitis 13: 67-78, 2019. – reference: 3) Smythies LE, et al: Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115: 66-75, 2005. – reference: 5) Denning TL, et al: Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 8: 1086-1094, 2007. – reference: 15) Christensen B, et al: Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol 17: 486-493, 2019. – reference: 1) Fritz T, et al: Crohn's disease: NOD2, autophagy and ER stress converge. Gut 60: 1580-1588, 2011. – reference: 8) Yamada S, et al: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol 14: 80, 2014. – reference: 14) Scribano ML: Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence. World J Gastroenterol 24: 2457-2467, 2018. – reference: 2) Cooney R, et al: NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16: 90-97, 2010. – reference: 6) Kamada N, et al: Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 118: 2269-2280, 2008. – reference: 12) Vijayakrishnan L, et al: Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 32: 25-34, 2011. – reference: 4) Smith PD, et al: Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 206: 149-159, 2005. – reference: 16) Danese S, Panés J: Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 147: 981-989, 2014. – reference: 18) Sandborn WJ, et al: Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374: 1754-1762, 2016. – reference: 10) Arseneau KO, Cominelli F: Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther 97: 22-28, 2015. – reference: 11) Yoshino T, et al: Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis 16: 2022-33, 2010. – reference: 9) Nakase H, et al: Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther 46: 873-882, 2017. – reference: 13) Sandborn WJ, et al: Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376: 1723-1736, 2017. – reference: 17) Vermeire S, et al: The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 60: 1068-1075, 2011. |
| SSID | ssib043658134 ssj0066765 ssib002821954 ssib005879745 ssib007485360 ssib058493862 ssib000940260 ssib002484664 |
| Score | 2.2596705 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 1759 |
| SubjectTerms | 獲得免疫 生物学的製剤 自然免疫 |
| Title | 4）病態からみえてきた炎症性腸疾患治療―現在そして未来にむけて |
| URI | https://www.jstage.jst.go.jp/article/naika/109/9/109_1759/_article/-char/ja |
| Volume | 109 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本内科学会雑誌, 2020/09/10, Vol.109(9), pp.1759-1763 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1883-2083 dateEnd: 99991231 omitProxy: true ssIdentifier: ssib007485360 issn: 0021-5384 databaseCode: KQ8 dateStart: 19130101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1Na9RANNQK4kX8xG96cE6yNZPMJDN4SrZZilJBaKHgYUmyyWEPrUh78dQsFC1FxYMWocWD-IHexIOg1P9icNebf8H3Xj42FQ-2wjIM877mvZlk3svOvDGMKyG3eZyYaYvbIQQoIpStKIpkS4QR_i0kEouOi83dcmYXxI1FuThx6FNj19LqSjQd3__ruZKDjCq0wbjiKdl9jGzNFBqgDuMLJYwwlP80xoIFHea3mdIscJl2mZIscLBUPgts8BKrikU41OJ3KpAqK55TtcyUFd1BhkgVVJxd4mwyDyoKRfiKQA7zAwJZzLOx4lvM9wmksbHcTCGJYYeQJdNt5lXSdS3UbfTHIRyPKjPMkxWoVsesqHhN1XS0idAlwoJVG-UqMg70BLRAQsm8GRIn0IwaxGmmfQIplK7qb8iE4qNyqIeJ_GByEppN2kk0bLEJuPqKAiEz3gJh1vOemCjqu0LzY6egL6Kyil-ZsGAJ7R78rh5Ml-Z6ZPEWLDnFJ5WkWIKUsmGWF9f71GuUqRsPo26sOOD-6Yb3wsv14s-V0eIOJpZdwnNpmEJseky3J9t4OZe7hIjbE7qaSkTvVkA8ENjtQ1Ry2HIdB-8NuXm74dRrgYnqGk6g2nOHAQT5vJmEUCpXN-9ccAW4kGN6YYOTzMdJDMFj1rZy6iRxuEm7uKektGWRmhUVvrZXXXAy-xByVds1yYOcP24cK0O_Ka9Q74Qx0Q9PGkfmys0tp4w74tfXjdHW-nB9M88288FGnn3Ls4d59ibPHuXZy9Hg8WjrwXDt7c_1z6Pnu8PBq-HHL6MXg-9rz0ZPdn9sv8uznTzbAvzh9vvhzus8-5AP1vLsKbScNhY6wXx7tlXefdLqc6koqUGqlRtaaQwBQBJKeOPHIg2V7qk05LEJsDCWTi-OZKLAKFKkDueAk-gkBqOdMSaXlpeSs8ZUBIiW6iVOyHvgfcbKjaROuArNqNdLY37OuF6YpXu3SHDT3c8kOP9f1BeMo-On8aIxuXJvNbkEXv5KdJkm1W-lS9BN |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=4%EF%BC%89%E7%97%85%E6%85%8B%E3%81%8B%E3%82%89%E3%81%BF%E3%81%88%E3%81%A6%E3%81%8D%E3%81%9F%E7%82%8E%E7%97%87%E6%80%A7%E8%85%B8%E7%96%BE%E6%82%A3%E6%B2%BB%E7%99%82%E2%80%95%E7%8F%BE%E5%9C%A8%E3%81%9D%E3%81%97%E3%81%A6%E6%9C%AA%E6%9D%A5%E3%81%AB%E3%82%80%E3%81%91%E3%81%A6&rft.jtitle=%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A%E9%9B%91%E8%AA%8C&rft.au=%E4%BB%B2%E7%80%AC%2C+%E8%A3%95%E5%BF%97&rft.date=2020-09-10&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=0021-5384&rft.eissn=1883-2083&rft.volume=109&rft.issue=9&rft.spage=1759&rft.epage=1763&rft_id=info:doi/10.2169%2Fnaika.109.1759&rft.externalDocID=article_naika_109_9_109_1759_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5384&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5384&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5384&client=summon |